Clearpoint Neuro Inc
NASDAQ:CLPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Clearpoint Neuro Inc
Total Current Liabilities
Clearpoint Neuro Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
Total Current Liabilities
$10.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
27%
|
CAGR 10-Years
3%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Current Liabilities
$5.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Current Liabilities
$1.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Current Liabilities
$7.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Current Liabilities
$16.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Current Liabilities
$2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
Clearpoint Neuro Inc
Glance View
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 80 full-time employees. The company went IPO on 2019-07-03. The Company’s product platforms include SmartFlow Cannula and ClearPoint Navigation System Software. The SmartFlow Cannula is being utilized in approved combination product clinical and preclinical studies by pharmaceutical companies and academic research customers for various research and clinical trials in connection with delivery of therapeutic agents. The ClearPoint Navigation System Software is a software for surgical planning, navigation to target, and device delivery. The Company’s software and MRI-compatible workstation coordinate with the scanner to effectively utilize intraprocedural MR images. This provides real-time navigational instruction for the neurosurgeon to reach the desired anatomical target with a high degree of precision.
See Also
What is Clearpoint Neuro Inc's Total Current Liabilities?
Total Current Liabilities
10.8m
USD
Based on the financial report for Dec 31, 2025, Clearpoint Neuro Inc's Total Current Liabilities amounts to 10.8m USD.
What is Clearpoint Neuro Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
3%
Over the last year, the Total Current Liabilities growth was 4%. The average annual Total Current Liabilities growth rates for Clearpoint Neuro Inc have been 17% over the past three years , 27% over the past five years , and 3% over the past ten years .
